Scientist Who Had Claimed Stem Cell Breakthrough Resigns From Japanese Research Institute
By Martin Fackler,
The New York Times
| 12. 19. 2014
Untitled Document
TOKYO — In a blow to the prestige of Japan’s scientific community, a government-backed research institute accepted the resignation of one of its highest-profile scientists on Friday after she failed to replicate research results that were once hailed as a breakthrough in stem cell research.
The institute, Riken, had given the researcher, Haruko Obokata, 31, three months to repeat the experiments that were the basis for her claimed discovery earlier this year of a remarkably simple way to make stem cells, a type of cell that could hold the key to futuristic medical treatments. On Friday, the institute announced that she had failed to replicate a new type of stem cell known as STAP cells, for stimulus-triggered acquisition of pluripotency, a term that refers to the cells’ ability to turn into any other type of cell.
That ability allows stem cells to grow into any kind of cell, like muscle and brain cells. By appearing to offer an easier way to make stem cells, Ms. Obokata’s claimed discovery of STAP cells seemed to bring doctors a step...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...